Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 51 of the 55 references it cites were found in a registry or an index; 17 of the 35 sources its claims cite were checked for support.

Epithelial-mesenchymal transition status is a remarkable biomarker for the combination treatment with avutometinib and defactinib in KRAS-mutated non-small cell lung cancer

Abstract

Background Recent therapeutic strategies for KRAS-mutated cancers that inhibit the MAPK pathway have attracted considerable attention. The RAF/MEK clamp avutometinib (VS-6766/CH5126766/RO5126766/CKI27) is promising for patients with KRAS-mutated cancers. Although avutometinib monotherapy has shown clinical activity in patients with KRAS-mutated cancers, effective combination strategies will be important to develop. Methods Using a phosphorylation kinase array kit, we explored the feedback mechanism of avutometinib in KRAS-mutated NSCLC cells, and investigated the efficacy of combining avutometinib with inhibitors of the feedback signal using in vitro and in vivo experiments. Moreover, we searched for a biomarker for the efficacy of combination therapy through an in vitro study and analysis using the The Cancer Genome Atlas Programme dataset. Results Focal adhesion kinase (FAK) phosphorylation/activation was increased after avutometinib treatment and synergy between avutometinib and FAK inhibitor, defactinib, was observed in KRAS-mutated NSCLC cells with an epithelial rather than mesenchymal phenotype. Combination therapy with avutometinib and defactinib induced apoptosis with upregulation of Bim in cancer cells with an epithelial phenotype in an in vitro and in vivo study. Conclusions These results demonstrate that the epithelial-mesenchymal transition status may be a promising biomarker for the efficacy of combination therapy with avutometinib and defactinib in KRAS-mutated NSCLC.

Overview

CoChat Summary

## TL;DR

Avutometinib activates a FAK/AKT bypass and reactivates ERK in KRAS-mutated NSCLC cells, and adding the FAK inhibitor defactinib is synergistic mainly in epithelial-phenotype cells. The paper argues that EMT status is a practical biomarker for response to the avutometinib + defactinib combination.

## Key findings

  • In NCI-H358 cells, avutometinib at concentrations above 1.5 µmol/L for 72 h left ~45% of cells surviving, and pFAK increased after 72 h of treatment.
  • In NCI-H2122 and NCI-H358 cells, ERK phosphorylation was strongly inhibited at 3 h but reactivated at 72 h, while FAK and AKT phosphorylation increased over 72 h.
  • Across nine KRAS-mutated NSCLC cell lines, the combination index (CI) for avutometinib + defactinib was <0.7 in 3 lines: NCI-H358, NCI-H2122, and NCI-H441; other lines were between 0.7 and 1.2.
  • EMT score correlated strongly with combination response, with a reported positive correlation of R² = 0.7937 between EMT score and CI value; the paper states that CI values above 0.7 corresponded to a stronger mesenchymal state.
  • In vivo, combination therapy maintained tumour suppression after treatment cessation, and the mean tumour weight was significantly lower than with avutometinib alone (p = 0.029). In the CDX model, the combination group had fewer Ki-67-positive cells and more TUNEL-positive cells than the avutometinib-alone group (p < 0.001 for both).

## Methods

  • Nine KRAS-mutated human NSCLC cell lines were studied in vitro; the paper also used an NCI-H358 cell-line-derived xenograft model in female BALB/c nu/nu mice (n = 6 per group).
  • The authors used RTK phosphorylation arrays, western blotting, CCK-8 viability assays, colony formation, siRNA knockdown of FAK and MYC, qRT-PCR for IGF-1, flow cytometry for cell cycle/apoptosis, scratch assays, and in vivo IHC/TUNEL analyses.
  • EMT status was assessed by western blotting for epithelial/mesenchymal markers and by GSVA of RNA-seq data from the Cell Model Passports database using epithelial and mesenchymal gene sets; drug interaction was quantified with CompuSyn combination index analysis.

## Limitations

  • The paper explicitly says that further clinical investigations are needed to validate EMT status as a biomarker for combination therapy.
  • The data availability statement says the supporting data are available from the authors upon reasonable request, which limits immediate reproducibility/access.
  • Evident from the text: the main mechanistic and biomarker conclusions are based on cell lines and one mouse xenograft model, so clinical generalizability to patients is not directly established.

Model-written summary. Check it against the paper before relying on it.

Integrity signals

Registry

Crossref · 10.1038/s41416-024-02727-2

Cites

51 of 51 references verified0 citation errors · 0 not checkable

Statistics

Nothing to recompute.

Verification

Claims the paper makes

13 Valid · 1 Not valid · 5 Not checked · 76 Own results and interpretations

51 more claims

Create a free account to see all 95 claims and every source verdict.

See all claims — free account
  • It may state two separate claims as one. 26
  • Probably not a substantial claim. 16
  • The quote only partly states this claim. 1

Create a free account to see these claims.

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

Each contradiction between two passages listed here was confirmed by an independent check.

1 of 1

Citations

Cites

Show all 55 references

Cited by

See all 15

Metadata

Authors
Yoshimura, A., Horinaka, M., Yaoi, T., Ono, H., Itoh, K., Yamada, T., Takayama, K., & Sakai, T.
Affiliations
Kyoto Prefectural University of Medicine (JP)
Corresponding author
Horinaka, Mano
Venue
British Journal of Cancer
Published
2024-05-31
Volume
131
Issue
2
Pages
361-371
ISSN
  • 0007-0920 (ISSN-L)
  • 1532-1827
OpenAlex
W4399201891
Cited by
15
References
55
Citations by year
2026: 5 · 2025: 8 · 2024: 2
FWCI
4.33
Type
journal article
Language
en
Open access
closed
Licence
Locations
  • British Journal of Cancer (publishedVersion)
  • PubMed (publishedVersion)
Funders
the Public Promoting Association Asano Foundation for Studies on Medicine
Topics
  • Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Kinase Regulation and GTPase Signaling
  • Health Sciences › Medicine › Oncology › Cancer Cells and Metastasis
Keywords
epithelial-mesenchymal transition, avutometinib, defactinib, KRAS mutation, non-small cell lung cancer, MAPK signaling, focal adhesion kinase, FAK inhibitors, combination therapy, biomarkers, apoptosis, building information modeling, feedback signaling
MeSH terms
Animals, Antineoplastic Combined Chemotherapy Protocols, Benzamides, Carcinoma, Non-Small-Cell Lung, Female, Humans, Lung Neoplasms, Mutation, Phosphorylation, Pyrazines, Sulfonamides, Biomarkers, Tumor, Proto-Oncogene Proteins p21(ras), Xenograft Model Antitumor Assays, Cell Line, Tumor, Mice, Focal Adhesion Kinase 1, Epithelial-Mesenchymal Transition

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

The claim verdicts this report counts are experimental: their accuracy is not yet measured.

A language model drew the claims from the paper on 2026-10-03, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).

A second model labelled each claim on 2026-10-03 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).

Cited sources are checked with a language model’s help (gpt-6-sol).

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Epithelial-mesenchymal transition status is a remarkable biomarker for the combination treatment with avutometinib and defactinib in KRAS-mutated non-small cell lung cancer. https://app.cochat.ai/papers/10.1038/s41416-024-02727-2
The paper
Yoshimura, A., Horinaka, M., Yaoi, T., Ono, H., Itoh, K., Yamada, T., Takayama, K., & Sakai, T. (2024). Epithelial-mesenchymal transition status is a remarkable biomarker for the combination treatment with avutometinib and defactinib in KRAS-mutated non-small cell lung cancer. British Journal of Cancer. https://doi.org/10.1038/s41416-024-02727-2

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.